SYMPOSIUM: Medical Management of LVAD Patients: Once the Chest is Closed, the Trouble Begins

Apr 4, 2019 8:00am ‐ Apr 4, 2019 9:45am


Description

What are We Treating with Heart Failure Therapy after MCS: the LV, the RV, the Periphery or Ourselves?
Maria Frigerio, MD

Antiplatelet Therapy: Fixed Dose or Functional Assays?
Jeffrey Teuteberg, MD

Time in Therapeutic Range: Is There an Optimal Way to Manage INR?
Douglas Jennings, PharmD

Pump Data: Do We Need It to Decide Changes in Therapy?
Francesco Moscato, PhD

DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (PRO)
Nir Uriel, MD

DEBATE: You Need Information From Invasive Hemodynamics to Properly Manage an LVAD (CON)
Emma Birks, MD, PhD

Speaker(s):

  • Maria Frigerio, MD, A.O. Niguarda Ca ' Granda, Milan, Italy
  • Jeffrey J. Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, United States
  • Douglas L. Jennings, PharmD, New York-Presbyterian Hospital, New York, NY, United States
  • Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria
  • Nir Uriel, MD, MSc, University of Chicago, Chicago, IL, United States
  • Emma J. Birks, MD, PhD, University of Louisville, Louisville, KY, United States
Tags: MCS

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content